Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Raw Materials (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Raw Materials data on record, last reported at $394000.0 in Q3 2025.

  • For Q3 2025, Raw Materials fell 52.7% year-over-year to $394000.0; the TTM value through Sep 2025 reached $394000.0, down 52.7%, while the annual FY2024 figure was $506000.0, 45.88% down from the prior year.
  • Raw Materials reached $394000.0 in Q3 2025 per BTAI's latest filing, down from $433000.0 in the prior quarter.
  • Across five years, Raw Materials topped out at $935000.0 in Q4 2023 and bottomed at $394000.0 in Q3 2025.
  • Average Raw Materials over 4 years is $674642.9, with a median of $682000.0 recorded in 2022.
  • Peak YoY movement for Raw Materials: soared 37.1% in 2023, then plummeted 52.7% in 2025.
  • A 4-year view of Raw Materials shows it stood at $682000.0 in 2022, then skyrocketed by 37.1% to $935000.0 in 2023, then plummeted by 45.88% to $506000.0 in 2024, then dropped by 22.13% to $394000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $394000.0 in Q3 2025, $433000.0 in Q2 2025, and $464000.0 in Q1 2025.